| Down syndrome screening: imagining the screening test of the future. | |
| | |
MedLine Citation:
|
PMID: 20465499 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Prenatal screening for Down syndrome (DS) is performed by risk calculation based on biochemical and biometric parameters. This way, approximately 75-85% of all DS cases can be detected. A way to improve detection rates is to search for new screening markers. Since the majority of biomarkers used in current DS screening are predominantly produced by the placenta, and the presence of an extra chromosome (as in DS) complicates placental development and function, it is plausible to assume that new potential screening markers may also originate from the placenta. Any alterations in these markers can be attributed to abnormal placental development and function. This article focuses on normal early placental development and function compared with that in DS pregnancies. Using this knowledge, we reason towards candidate biomarkers that may be useful in screening for DS. |
| | |
Authors:
|
M P H Wendy Koster; Kirsten M Heetkamp; Jeroen L A Pennings; Annemieke de Vries; Gerard H A Visser; Peter C J I Schielen |
Related Documents
:
|
2216209 - The twin-twin transfusion syndrome. 8248469 - Room for improvement? detecting autosomal trisomies without serum screening. 21737909 - Rheumatoid arthritis associated with the use of sandostatin® lar® depot in a patient ... 8159379 - Umbilical artery steal syndrome and distal gangrene in a case of twin-twin transfusion ... 12877619 - Percutaneous mechanical thrombectomy for the management of venous thoracic outlet syndr... 8544199 - Monozygotic twins with chromosome 22q11 deletion and discordant phenotype. 3978349 - De clérambault's syndrome--a nosological entity? 7791159 - Prevalence of primary sj?gren's syndrome in china. 1295149 - Iga nephropathy (igan) presenting with the nephrotic syndrome. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Expert review of molecular diagnostics Volume: 10 ISSN: 1744-8352 ISO Abbreviation: Expert Rev. Mol. Diagn. Publication Date: 2010 May |
Date Detail:
|
Created Date: 2010-05-14 Completed Date: 2010-08-12 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101120777 Medline TA: Expert Rev Mol Diagn Country: England |
Other Details:
|
Languages: eng Pagination: 445-57 Citation Subset: IM |
Affiliation:
|
National Institute for Public Health and the Environment (RIVM), PO Box 1, NL-3720BA Bilthoven, The Netherlands. wendy.koster@rivm.nl |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Biological Markers
/
metabolism* Down Syndrome / diagnosis*, genetics Female Genetic Testing / methods* Hormones / metabolism Humans Metalloproteases / metabolism Placenta / growth & development, metabolism Pregnancy Prenatal Diagnosis / methods Superoxide Dismutase / metabolism |
| Chemical | |
Reg. No./Substance:
|
0/Biological Markers; 0/Hormones; EC 1.15.1.1/Superoxide Dismutase; EC 3.4.-/Metalloproteases |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: miRNAs as molecular biomarkers of cancer.
Next Document: ST2: a novel biomarker for heart failure.